Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis

Takahashi, Masaaki; Kushida, Kazuhiro; Hoshino, Hironobu; Miura, Masaru; Ohishi, Tsuyoshi; Inoue, Tetsuo

doi:10.1046/j.1365-2265.1997.2221055.x

Cited by 23 publications

(9 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our RN group had significantly higher serum AP levels (P < 0.01, Fig. 2), a parameter that might indeed reflect increased bone turnover (21). Serum osteocalcin, repeatedly found by only one group as increased in patients with RN (4, 7, 15), was not significantly modified in our study (Fig.…”

Section: Discussioncontrasting

confidence: 65%

Particularities of Bone Metabolism and Calcium Regulators in a Group of Young Males with Idiopathic Hypercalciuria and Relapsing Kidney Lithiasis

Pricop¹

2014

Acta Endo (Buc)

View full text Add to dashboard Cite

Background. Idiopathic hypercalciuria is a risk factor for nephrolithiasis. Both renal stones and hypercalciuria are associated with lower bone mineral density (BMD), but the relationship between these modifications is not completely understood.Aims. To evaluate some metabolic particularities possibly related to relapsing nephrolithiasis (RN) in young male patients.Methods. We performed a crosssectional study including a group of 30 young male patients with RN and a group of 30 healthy, age and BMI (body mass index) matched controls (CTR). We evaluated calcium and phosphate metabolism, bone remodeling markers alkaline phosphatase (AP) and osteocalcin in serum and 24-hour urine samples, and lumbar and hip BMD.Results. We observed higher values of serum calcium (P<0.05) and 24 hour urinary calcium (P<0.001) in the RN group. Parathyroid hormone (PTH) and AP were also higher in the RN group (P<0.01), whereas serum 25OH-D 3 was lower (P<0.01). BMD, T and Z scores were lower in the RN group in both the lumbar (P<0.01) and hip (P<0.05) regions. Conclusions.Young male patients with hypercalciuric RN have lower BMD and higher bone turnover. Higher PTH levels related to vitamin D deficiency may contribute to bone demineralization in certain cases.

show abstract

Section: Discussioncontrasting

confidence: 65%

Particularities of Bone Metabolism and Calcium Regulators in a Group of Young Males with Idiopathic Hypercalciuria and Relapsing Kidney Lithiasis

Pricop¹

2014

Acta Endo (Buc)

View full text Add to dashboard Cite

show abstract

“…ALP is considered a marker of bone remodeling (60, 100) and a high correlation exists between bone-specific and total ALP (93). In this study, ALP decreased with GSK232802A treatment, suggesting that GSK232802A therapy may have decreased bone resorption.…”

Section: E763 Estrogen Decreases Body Weight In Monkeysmentioning

confidence: 48%

Selective estrogen receptor modulator promotes weight loss in ovariectomized female rhesus monkeys (Macaca mulatta) by decreasing food intake and increasing activity

Sullivan

Shearin

Koegler

et al. 2012

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Sullivan EL, Shearin J, Koegler FH, Cameron JL. Selective estrogen receptor modulator promotes weight loss in ovariectomized female rhesus monkeys (Macaca mulatta) by decreasing food intake and increasing activity. Am J Physiol Endocrinol Metab 302: E759 -E767, 2012. First published January 17, 2012; doi:10.1152/ajpendo.00327.2011.-The effect of hormone replacement therapy (HRT) on body weight in postmenopausal women is controversial, with studies reporting an increase, a decrease, and no change in body weight. To examine estrogen receptor actions on body weight, we investigated the effects of treatment with a selective estrogen receptor modulator (SERM) on body weight, food intake, and activity and metabolic rate in a nonhuman primate model. Eighteen ovariectomized female rhesus monkeys were treated with a nonsteroidal SERM (GSK232802A, 5 mg/kg po) for 3 mo. GSK232802A decreased lutenizing hormone (P Ͻ 0.0001) and follicle-stimulating hormone levels (P Ͻ 0.0001), consistent with the estrogenic action of the compound. GSK232802A treatment produced a small but sustained weight loss (4.6 Ϯ 1.0%, P Ͻ 0.0001) and reduced adiposity (P Ͻ 0.0001), which was due at least in part to a suppression of food intake (3.6 Ϯ 3.7%, P Ͻ 0.0001). Physical activity increased during the 3rd mo of treatment (P ϭ 0.04). Baseline activity level and the change in activity due to treatment were correlated, with the most sedentary individuals exhibiting increased physical activity during the 1st mo of treatment (P ϭ 0.02). Metabolic rate did not change (P ϭ 0.58). These results indicate that GSK232802A treatment reduces body weight and adiposity in ovariectomized nonhuman primates by suppressing food intake and increasing activity, particularly in the most sedentary individuals. These findings suggest that SERM treatment may counteract weight gain in postmenopausal women.hormone replacement therapy; obesity; menopause; body fat WOMEN GAIN WEIGHT IN ADULTHOOD during the menopausal transition (16,31,45,50,53,56). However, it is unclear whether weight gain is due to age-related changes in metabolism and lifestyle, such as eating more or exercising less, or due to the decrease in ovarian hormones that occurs with menopause. The effects of hormone replacement therapy (HRT) on the body weights of postmenopausal women are controversial. Many women believe that HRT increases body weight, and 18% of hormone replacement users report weight gain as the main reason for discontinuing HRT (63,78). However, the idea that HRT increases body weight is supported by only a few studies (5, 36). The majority of studies report either that postmenopausal women on HRT have lower body weight than nonusers (82, 83) or that HRT decreases (28, 29, 47) or does not affect postmenopausal weight gain (10,84,86,91), and a few studies report that HRT causes weight loss (20). The controversy around the effects of HRT on body weight in postmenopausal women may be related in part to differing effects of the various HRT regimens that are in common use, including differences i...

show abstract

“…Humans in infancy and at puberty show 2 physiological blood bone ALP concentration peaks, with troughs in mid-childhood and at the end of adolescence [14,15]. Furthermore, for postmenopausal women with high bone turnover, bone ALP concentrations were found to be significantly higher than for those in premenopausal [16][17][18].…”

Section: Introductionmentioning

confidence: 97%

Evaluation of serum bone alkaline phosphatase activity in patients with liver disease: Comparison between electrophoresis and chemiluminescent enzyme immunoassay

Zhan

Watanabe

Shimoda

et al. 2016

Clinica Chimica Acta

View full text Add to dashboard Cite

show abstract

Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis

Abstract: Preference can be given to bone AP by enzymatic immunoassay over total AP based on their clinical utility during the menopause; however, no preference can be given to bone AP over total AP in established osteoporosis.

Cited by 23 publications

References 12 publications

Particularities of Bone Metabolism and Calcium Regulators in a Group of Young Males with Idiopathic Hypercalciuria and Relapsing Kidney Lithiasis

Particularities of Bone Metabolism and Calcium Regulators in a Group of Young Males with Idiopathic Hypercalciuria and Relapsing Kidney Lithiasis

Selective estrogen receptor modulator promotes weight loss in ovariectomized female rhesus monkeys (Macaca mulatta) by decreasing food intake and increasing activity

Evaluation of serum bone alkaline phosphatase activity in patients with liver disease: Comparison between electrophoresis and chemiluminescent enzyme immunoassay

Contact Info

Product

Resources

About